Immune checkpoint-inhibiting antibodies are now established US Food and Drug Administration (FDA)-approved cancer immunotherapies that have been found to be beneficial in both PD-L1 positive and PD-L1 negative patients [15]. The gene discussed is CD274; the disease is cancer.